Please assess the completion status of the following clinical trial:

Trial Title: Surface Stimulation for Female Sexual Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult women ≥ 18 years of age~* Sexually active ≥ 1 time per month (≥ 2 times per month preferred)~* Score of 19 or less on a 6-question set of the Female Sexual Function Index (FSFI) survey~* Neurologically stable~* Ambulatory~* Capable of giving informed consent~* English speaking~* Capable and willing to follow study procedures~Exclusion Criteria:~* Men~* Women ≤ 17 years of age~* Pregnant or planning to get pregnant during the study period~* Clinically diagnosed neurological bladder dysfunction~* Prior experience with PTNS or DGNS~* Current use of transcutaneous electrical nerve stimulation (TENS) on pelvis, back, or legs~* Implanted pacemaker, defibrillator, spinal cord stimulator, or sacral root stimulator~* Taking flibanserin~* Taking any investigational drug~* History of neurologic diseases or impairments~* Any other factors that the investigators feel would place the patient at increased risk from this study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Posterior Tibial Nerve Stimulation Group (Type: EXPERIMENTAL): Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over their posterior tibial nerve, that is in the area of the ankle, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.
- Dorsal Genital Nerve Stimulation Group (Type: EXPERIMENTAL): Subjects in this group will have transcutaneous electrical nerve stimulation electrodes placed on the skin surface over the dorsal genital nerve, that is above and/or on the lateral side of the clitoris, and receive stimulation for 30 minutes in weekly sessions for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).